FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic randomised control trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer. PMID 41299751 · Trials · 2025-Nov-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| HPV self-sampling for cervical cancer screening among women living with HIV in Ghana: protocol for a hybrid type 1 effectiveness-implementation randomized controlled trial. PMID 41299750 · Trials · 2025-Nov-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial. PMID 40623005 · Nephrol Dial Transplant · 2025-Nov-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO-trial): a phase 3 multicentre stepped-wedge cluster-randomised noninferiority trial]. PMID 41725589 · Ned Tijdschr Geneeskd · 2025-Nov-25 The trial is a Phase III randomized oncology study with a time-to-event efficacy endpoint (overall survival). However, the intervention being evaluated is active surveillance versus standard surgery following neoadjuvant chemoradiotherapy. The drug component (chemoradiotherapy) is part of the prior treatment for both arms, not the intervention being compared. Therefore, the study lacks a drug-containing intervention as required for inclusion. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Faecal microbiota transplantation for primary Clostridioides difficile infection. PMID 41292332 · Tidsskr Nor Laegeforen · 2025-Nov-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study. PMID 41290609 · Nat Commun · 2025-Nov-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Safety and Efficacy of Remote Ischaemic Conditioning for Acute Ischaemic Stroke Treated with Mechanical Thrombectomy (RECAST-MT): rationale and design. PMID 41290408 · Stroke Vasc Neurol · 2025-Nov-25 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. PMID 41123939 · JAMA · 2025-Nov-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial. PMID 41114973 · JAMA · 2025-Nov-25 This is a randomized clinical trial on lung cancer screening, but it does not meet the core eligibility criteria: (1) It is not a Phase III/IIIb or Phase II/III trial of a therapeutic intervention for a malignant neoplasm; it is a Phase unspecified pragmatic trial of a digital health intervention for screening uptake. (2) The intervention is not a drug-containing regimen. (3) The primary efficacy endpoint is screening completion (a binary proportion), not a time-to-event outcome (e.g., OS, PFS, DFS) analyzed with Kaplan-Meier or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. PMID 40763276 · Blood Adv · 2025-Nov-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 2 Panel · risk unclear |
| The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China. PMID 41441657 · Vaccines (Basel) · 2025-Nov-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An Alternative Treatment Effect Measure for Time-to-Event Oncology Randomized Trials. PMID 41374954 · Cancers (Basel) · 2025-Nov-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial. PMID 41297981 · JACC Cardiovasc Interv · 2025-Nov-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| LIVERATION trial: a multicentre European randomised study on radiofrequency margin coagulation and its impact on oncological outcomes after liver surgery - study protocol. PMID 41290310 · BMJ Open · 2025-Nov-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Antibiotic stewardship in suspected neutropenic fever (ASTERIC trial): a multicentre, type 1 hybrid effectiveness-implementation, stepped-wedge, randomised controlled trial study protocol. PMID 41290295 · BMJ Open · 2025-Nov-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effectiveness and cost-effectiveness of risk-adapted colorectal cancer screening: a randomized controlled trial and modeling analysis. PMID 41287073 · Mil Med Res · 2025-Nov-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin. PMID 41286911 · Cost Eff Resour Alloc · 2025-Nov-24 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study. PMID 41286676 · BMC Neurol · 2025-Nov-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy analysis of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma. PMID 41286133 · Sci Rep · 2025-Nov-24 The record describes a randomized, controlled trial in oncology (hepatocellular carcinoma) with drug interventions (anlotinib, sintilimab) and time-to-event efficacy endpoints (PFS, OS). However, the trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, which is a required criterion. Additionally, while time-to-event outcomes are reported, the abstract does not provide Kaplan-Meier curves or hazard ratios, which are key for digitization. Therefore, eligibility cannot be confirmed due to missing explicit phase evidence. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of Total Mesorectal Excision (TME) quality on 3-year overall survival in low rectal cancer based on the LASRE trial. PMID 41285886 · Sci Rep · 2025-Nov-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bibliometric evaluation of research trends and hotspots concerning the interaction between immune checkpoint inhibitors and glioma. PMID 41284174 · Discov Oncol · 2025-Nov-24 This is a bibliometric analysis of literature trends, not an original report of a clinical trial. It does not contain primary efficacy data from a randomized trial with a time-to-event endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. PMID 41276263 · Cochrane Database Syst Rev · 2025-Nov-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Treatment, Craving, and Affect During the First Week of the Quit Attempt. PMID 40358028 · Nicotine Tob Res · 2025-Nov-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial. PMID 41284548 · Lancet · 2025-Nov-22 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial. PMID 41275111 · J Headache Pain · 2025-Nov-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial. PMID 41271680 · Nat Commun · 2025-Nov-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy of migalastat in females with Fabry disease. PMID 40897525 · J Med Genet · 2025-Nov-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens. PMID 41301076 · Cancers (Basel) · 2025-Nov-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Oncological Outcomes of Patients Undergoing Radical Prostatectomy with Extended versus Indocyanine-Guided Lymphadenectomy: Midterm Follow-Up of PersonalymPCa Clinical Trial. PMID 41264563 · Urol Int · 2025-Nov-20 The trial is randomized and reports time-to-event efficacy (biochemical recurrence-free survival), but the intervention is a surgical technique (ICG-guided lymphadenectomy) not a drug-containing regimen. Therefore, it does not meet the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Psychometric evaluation of a pediatric functional constipation symptom diary using randomized phase 3 clinical trial data. PMID 41264134 · J Patient Rep Outcomes · 2025-Nov-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Breast surgery for metastatic breast cancer. PMID 41263247 · Cochrane Database Syst Rev · 2025-Nov-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. PMID 41259756 · N Engl J Med · 2025-Nov-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial. PMID 41101087 · Vaccine · 2025-Nov-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. PMID 41082707 · J Clin Oncol · 2025-Nov-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 2 Panel · risk unclear |
| Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation. PMID 41043099 · J Clin Oncol · 2025-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study. PMID 39965795 · Chin Med J (Engl) · 2025-Nov-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumour cells and survival in minimally invasive rectal cancer surgery: study protocol for a randomised controlled trial (ARVECTS study). PMID 41263842 · BMJ Open · 2025-Nov-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Developing couple‑centered nursing interventions for male infertility: a mixed-methods protocol. PMID 41258092 · Reprod Health · 2025-Nov-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Preventive effects of combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereus tablets on radiation pneumonitis-associated with cyberknife treatment for pulmonary malignancies. PMID 41257942 · Ann Clin Microbiol Antimicrob · 2025-Nov-19 The record describes a randomized trial of a probiotic intervention to prevent radiation pneumonitis in lung cancer patients receiving CyberKnife therapy. While it meets criteria for oncology, human, randomized, time-to-event endpoint, and drug intervention, it does not meet the core requirement of being a definitive (Phase III/IIIb or Phase II/III) trial of a systemic anti-cancer drug regimen. The study is a supportive care/prevention trial, and the phase is not specified in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of a theory-driven, disclosure-based family support programme on fear of cancer recurrence for couples coping with breast cancer: protocol for a multi-centre randomised controlled trial. PMID 41257879 · Trials · 2025-Nov-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Chinese herbal medicine granules plus chemotherapy in patients with EGFR-mutated advanced lung adenocarcinoma post-progression on first-line EGFR-TKI: study protocol for a multicenter, double-blind, randomized controlled trial. PMID 41257744 · BMC Complement Med Ther · 2025-Nov-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Agreement between face-to-face and photograph and video assessments in children with Bell's palsy: secondary analysis of a randomised controlled trial. PMID 40634111 · Arch Dis Child · 2025-Nov-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial. PMID 41254229 · Commun Med (Lond) · 2025-Nov-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial. PMID 41195787 · J Am Heart Assoc · 2025-Nov-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Metformin in conjunction with doxycycline is not superior to doxycycline monotherapy for hidradenitis suppurativa; results of a phase III double-blinded randomized placebo- controlled trial. PMID 41091742 · Br J Dermatol · 2025-Nov-18 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. PMID 40892617 · J Am Coll Cardiol · 2025-Nov-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa. PMID 40794600 · Br J Dermatol · 2025-Nov-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. PMID 40737559 · Br J Dermatol · 2025-Nov-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up). PMID 40581082 · Br J Dermatol · 2025-Nov-18 The record describes a Phase IIIb/IV randomized trial of upadacitinib for atopic dermatitis, which is a non-oncology condition. The primary efficacy endpoint is a categorical response (EASI 90) and does not involve time-to-event analysis (e.g., OS, PFS, KM curves). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Strategies to improve healthcare team communication structure and quality in resource-variable childhood cancer hospitals (TeamTalk): a study protocol. PMID 41250257 · Implement Sci Commun · 2025-Nov-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |